The startup develops therapeutic drugs utilizing a proprietary recombinant factor VIIa (rFVIIa) molecule, CT-001, for the prevention and treatment of acute bleeding and coagulation disorders. Their focus on biologics enables targeted therapies that enhance treatment outcomes for traumatic injuries, ultimately aiming to improve survival rates among young patients.
Funding
$38M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Acute bleeding, encompassing conditions like postpartum hemorrhage, intracranial hemorrhage, and traumatic injuries, remains a leading cause of death, with a significant percentage of hemorrhage-related deaths potentially preventable. Currently, there are limited or no approved drugs specifically designed to treat acute bleeding episodes.
Solution
Coagulant Therapeutics is developing a portfolio of hemostatic agents, including CT-001, a novel recombinant Factor VIIa (rFVIIa) molecule, and a library of nanobodies targeting Activated Protein C (APC), to address the unmet medical need for acute bleeding treatments. CT-001 is engineered for enhanced activity and safety, designed to rapidly clear from the system, reducing the risk of thrombo-embolic events. The APC-targeting nanobodies, including lead candidates CT-003 and CT-005, selectively modulate APC functions to ameliorate trauma-induced coagulopathy and other bleeding disorders. These biologics-based therapeutics aim to provide rapid hemostatic control and improve outcomes in various acute bleeding indications.
Target Audience
The primary target audience includes medical professionals treating patients experiencing acute bleeding events, such as those resulting from trauma, surgery, or obstetric complications, as well as clinical researchers focused on coagulation disorders and acute care.
Features
- CT-001: A novel rFVIIa variant engineered for faster clearance and superior efficacy in pre-clinical models.
- APC Nanobody Library: A collection of llama-derived nanobodies targeting APC, enabling selective modulation of its coagulation, inflammation, and histone cleavage functions.
- CT-003/CT-005: Lead nanobody candidates that shift PAR1 signaling towards anti-inflammation and cytoprotection, potentially ameliorating endotheliopathy.
- Demonstrated superior potency and safety of CT-001 compared to rFVIIa in multiple murine acute bleeding models.
- CT-001 corrects APTT of hypocoagulable plasma, indicating pro-hemostatic activity under coagulopathic conditions.
- Nanobodies exhibit high stability, making them suitable for liquid formulation in diverse settings.